Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

ceva-phylaxia co.ltd., budapest, hungary (0000014679) szallas u. 5.,1107,budapest,hu - cell-associated live recombinant turkey herpesvirus (rhvt/nd/ibd), expressing the fusion protein of newcastle disease vi - ΠΥΚΝΟ ΣΚΕΥΑΣΜΑ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΕΝΕΣΙΜΟΥ ΕΝΑΙΩΡΗΜΑΤΟΣ - - - cell-associated live recombinant turkey herpesvirus (rhvt/nd/ibd), expressing the fusion protein of newcastle disease vi 3000,00 c.so.s.sus - - live viral vaccines - Ορνίθια; Εμβρυοφόρα αυγά κότας - Χρόνοι αναμονής: Ορνίθια 0 Ημέρες Κρέας και εδώδιμοι ιστοί

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - Χοίροι - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

itf hellas a.e. (0000008180) areos 103 and agias triados 36, palaio faliro, 17562 - iron proteinsuccinylate; calcium folinate pentahydrate - powder and solvent for oral solution - iron proteinsuccinylate (8000001419) 800mg; calcium folinate pentahydrate (0041927893) 0,235mg - iron in combination with folic acid

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

glaxosmithkline aebe - ΔΙΦΘΕΡΙΤΙΚΉ ΑΝΑΤΟΞΊΝΗ, ΠΡΟΣΡΟΦΗΜΈΝΟ, ΤΟΞΟΕΙΔΈΣ ΤΟΥ ΤΕΤΆΝΟΥ, purified pertussis toxoid (pt xd), ΝΗΜΑΤΟΕΙΔΉ ΑΙΜΟΣΥΓΚΟΛΛΗΤΊΝΗ (fha), pertactin (69 kda outer membrane protein-69k) - ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - 0,5ml/vial (1 dose) - ineof00157 - diphtheria toxoid, adsorbed - 0.000000 ; 8000040440 - tetanus toxoid - 0.000000 ; ineof01454 - purified pertussis toxoid (pt xd) - 8.000000 mcg; ineof01236 - filamentous haemagglutinin (fha) - 8.000000 mcg; ineof01237 - pertactin (69 kda outer membrane protein-69k) - 2.500000 mcg - pertussis, purified antigen, comb. with toxoids

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

biotest pharma gmbh (0000003549) landsteinerstr. 5, dreieich, d-63303 - human plasmaprotein - solution for infusion - 200g/l - human plasmaprotein (8000028333) 96% - albumin

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

octapharma (ip) sprl (0000010636) alle de la recherche 65, anderlecht, bruxelles - capitale, 1070 - human plasmaprotein - solution for infusion - 250g/l - human plasmaprotein (8000028333) 250g - albumin

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

octapharma (ip) sprl (0000010636) alle de la recherche 65, anderlecht, bruxelles - capitale, 1070 - human plasmaprotein - solution for infusion - 40g/l - human plasmaprotein (8000028333) 40g - albumin

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

glaxosmithkline biologicals sa (0000003483) rue de l΄ institut 89, rixensart, b-1330 - diphtheria toxoid; poliomyelitis virus type 3; poliomyelitis virus type 2; poliomyelitis virus type 1; haemophilus infl. type b polys.conj.t.toxoid; tetanus toxoid; pertactin (69kda outer membrane protein-69k); filamentous haemagglutinin (fha); pertussis toxoid(pt) - powder & suspension for suspension for injection - in pre-filled syringe - diphtheria toxoid (8000000804) 30iu; poliomyelitis virus type 3 (8000000485) 32du; poliomyelitis virus type 2 (8000000484) 8du; poliomyelitis virus type 1 (8000000483) 40du; haemophilus infl. type b polys.conj.t.toxoid (8000001810) 10mcg; tetanus toxoid (8000024353) 40iu; pertactin (69kda outer membrane protein-69k) (8000001814) 8mcg; filamentous haemagglutinin (fha) (8000001813) 25mcg; pertussis toxoid(pt) (8000001811) 25mcg - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

biotest pharma gmbh (0000003549) landsteinerstr. 5, dreieich, d-63303 - human plasmaprotein - solution for infusion - 100g/l - human plasmaprotein (8000028333) 100mg - immunoglobulins, normal human, for intravasc. adm.

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

biotest pharma gmbh (0000003549) landsteinerstr. 5, dreieich, d-63303 - human plasmaprotein - solution for infusion - 50g/l - human plasmaprotein (8000028333) 50mg - immunoglobulins, normal human, for intravasc. adm.